







ΕΠΙΠΟΛΑΣΜΟΣ ΜΥΟΣΚΕΛΕΤΙΚΩΝ ΕΚΔΗΛΩΣΕΩΝ ΣΕ ΑΣΘΕΝΕΙΣ ΜΕ ΙΔΙΟΠΑΘΗ ΦΛΕΓΜΟΝΩΔΗ ΝΟΣΟ ΤΟΥ ENTEPOY ΚΑΙ ΕΠΙΔΡΑΣΗ ΤΩΝ ΒΙΟΛΟΓΙΚΩΝ ΘΕΡΑΠΕΙΩΝ: ΕΜΠΕΙΡΙΑ ΕΝΟΣ ΚΕΝΤΡΟΥ

Κόγιας Δ., Σκένδρος Π., Ρίτης Κ., Παπαγόρας Χ., Κουκλάκης Γ.

Ά Πανεπιστημιακή Παθολογική Κλινική , ΠΓΝ Αλεξανδρούπολης

Χαλκιδική, 5 Σεπτεμβρίου 2021

Τύποι μυοσκελετικής προσβολής στην IBD

- Αξονική προσβολή
- Περιφερική προσβολή
 - «Τύπου 1» αρθρίτιδα
 - «Τύπου 2» αρθρίτιδα
 - Ενθεσίτιδα
 - Δακτυλίτιδα

Gut 1998;42:387–391

World J Gastroenterol 2009 May 28; 15(20): 2449-2455

Journal of Crohn's and Colitis, 2017, 631–642 doi:10.1093/ecco-jcc/jjw199 Advance Access publication December 7, 2016 Review Article




Review Article

The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

JCC JOHNAL of CROPICS and COLITIS


Maren C. Karreman,^{a,b} Jolanda J. Luime,^a Johanna M. W. Hazes,^a Angelique E. A. M. Weel^{a,b}



Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study

Alvilde Maria Ossum^{a,b}, Øyvind Palm^c, Milada Cvancarova^d, Inger Camilla Solberg^a, Morten Vatn^e, Bjørn Moum^{a,b}, Marte Lie Høivik^a (1) and the IBSEN study group

- Κοόρτη εισδοχής IBD
- Ρευματολογική εκτίμηση και ερωτηματολόγιο
- Έκβαση: αποκλειστικά περιφερική αρθρίτιδα IBD (ιατρός) και αποκλειστικά περιφερική ΣπΑ (ASAS)
- Τα 20 έτη συμπλήρωσαν 441 ασθενείς



Overview of the effects of drugs approved for the treatment of IBD and SpA across the main disease manifestations

Drug	Crohn's Disease	Ulcerative colitis	Axial Disease, Enthesitis, Dactylitis	Peripheral Arthritis (PsA)
NSAIDs	Avoid in active disease	Avoid in active disease	+	+
Systemic Glucocorticoids	+	+	-	Lowest exposure possible
Sulphasalazine	+	+	-	+
Methotrexate	+	-	-	+
Leflunomide	-	-	-	+
Azathioprine	+	+	-	-
Infliximab				
Adalimumab	+	+	+	+
Golimumab	-	+	+	+
Certolizumab	+	-	+	+
Etanercept	-	-	+	+
Ustekinumab	+	+	Enthesitis & dactylitis only	+
Vedolizumab	+	+	-	-
Secukinumab	Arraid	المناط		
Ixekizumab	Avoid	Avoid	+	+
Tofacitinib	-	+	Efficacious, not approved	+

Zioga N, Kogias D et al. MJR (submitted)

Σκοπός

• Η αναζήτηση μυοσκελετικών εκδηλώσεων σε ασθενείς με ΙΦΝΕ και η επίδραση σε αυτές των βιολογικών θεραπειών που χορηγούνται για την ΙΦΝΕ.

Υλικό-Μέθοδοι

- Ασθενείς με ΙΦΝΕ που εξετάσθηκαν στο Τμήμα μας τα τελευταία 5 έτη
- Ερωτηματολόγιο ανίχνευσης μυοσκελετικών συμπτωμάτων
- BASDAI και BASFI score
- Harvey Bradshaw Index (HBI) και Partial Mayo Score

Εκτίμηση ενεργότητας της αξονικής προσβολής

Bati	Ankylosing Spon	BASFI *C lin et al. J Rheumatol	1994 21; 2281-85
Date		Patient Name	
	aw a mark on each line activities, during the <u>p</u>	below to indicate your ability ast week:	with each of the
1. Putting on	your socks or tights without h	nelp or aids (e.g. sock aids)?	
EASY	0		IMPOSSIBLE
2 Bending fo		10 up a pen from the floor without an aid?	
	I wai d if offi the waist to pick t	A 1450 House Laboratory (1911)	
EASY	0	10	IMPOSSIBLE
3. Reaching	up to a high shelf without help	o or aids (e.g. helping hand)?	
EASY			IMPOSSIBLE
	0	10	
4. Getting up	out of an armless dining roor	m chair without using your hands or ar	ny other help?
EASY	0	40	IMPOSSIBLE
5. Getting un	off the floor without any help	from lying on your back?	
	The state of the s	, , , , . ,	
EASY	0	10	IMPOSSIBLE
6. Standing	unsupported for 10 minutes v	vithout discomfort?	
EACY		24	IMPOSSIBLE
EASY	0	10	IMPOSSIBLE
7. Climbing	12-15 steps without using a h	handrail or walking aid (one foot on ea	ch step)?
EASY			IMPOSSIBLE
	0	10	
8. Looking o	ver your shoulder without turn	ning your body?	
EASY			IMPOSSIBLE
	0	10	
9. Doing ph	ysically demanding activities	(e.g. physiotherapy exercises, garden	ing or sports)?
EASY			IMPOSSIBLE
	0	10	
10. Doing a	full day activities whether it b	e at home or work?	
F46W			IMPOSSIBLE
EASY	0	10	IIII OGGIDEE

Numer							-					
Date:									Pleas	ne drav onlin ye	v a meet, on each line to ur situation in the peet ?	elow to days:
	ould you out week?		be the	e eve	nill k	evel of	Charing	ue / 6	ireda	ess ye	n have experiences	1 .
	som f	Ŧ		6	4		-	-	·	-	white management	
	ould you o		her the	over	all le	well of	A/5 n	nck, h	anck o	er hiju	pain you have had	
		+	1	-	+	+		Ŧ	Ŧ	Ŧ	many samera	
How w	ould you o	have.	be the had is	the	alli le past	week.	puin.	(aws)	ling i	n jebr	to other than neck,	
	ould you o							miljori	you!	have	had in the past wee	ek:
	-			1	4		1		1	-	- my same	
	ould you o						more	ing s	dffae	is yes	have had in the	
	energy (1	1	1	1	1	ı	Ŧ	1	ŀ	And nones	- 1
How Is	ng did you	ar ma	raing	s tállic	eese li	ast for	on th	e tione	r years	wake	up?	
	9	_	1 %	-	8	+	736	_	N.	7%	2 hours or more	
	-	Øł.	ĢII	(9)	(0)	TQ.	100	97	(OI		199	
										and co	i - January Landines II kuli dan da	

Εκτίμηση ενεργότητας της εντερικής νόσου

Alberta Health Services	SIBD CLINIC
Modifie Harvey Bradshaw Index	Date:
Assessment for Crohn's Disease	Patient Name:
Activity	Date of Birth: PHN/ULI:
Patient, please complete Questions 1, 2 & 3.	
Base your answers on how you felt yesterday	General Well-being Descriptors
1. General Well-being (see descriptors) Very well = 0 Slightly below Par = 1 Poor = 2 Very Poor = 3 Terrible = 4 2. Abdominal Pain (see descriptors) None = 0 Mild = 1 Moderate = 2 Severe = 3 3. Number of Liquid or Soft Stools per day (Yesterday)	General well being includes fatigue in the overall rating and how you feel today. Record the worst you have felt today. Compare yourself to someone else of your age, how would they rank their general wellbeing? Below are some descriptors to help you rank your category of general well being. • Very Well: General health is not generally a problem. You're feeling very good or great and under control. • Slightly Below Par: You're getting through things but feeling below par and not normal. Something overall is preventing you from saying "I feel wonderful". You're feeling good but not great. You can work, socialize, and function on a day to day basis. • Poor: Your symptoms bother you. You occasionally miss work, school, or social activities. You have some embarrassing moments with fecal incontinence. You have diarrhea, abdominal pain, fatigue, and basically just feeling unwell, but you are still able to function. You're getting through the day, doing all your normal stuff but it is a struggle. • Very Poor: Your getting through a part of the day, but can't do you're your normal stuff. You can't atted social events in evening. You sometime leave home from work early. You feel pretty bad and are not doing much activity — only those absolutely necessary. Your symptoms interfere with life considerably, you don't go out or are fearful when out, you miss a lot of school or work. Fecal incontinence happens several times per week. • Terrible: You're unable to function. You can't manage the basics and
Physician, please complete Question 4	you're almost bedridden. This is the worse you have ever been. You're not working.
4. Additional Manifestations None = 0	
None = 0 Arthalgia = 1 Uveitis = 1 Erythema Nodosum = 1 Aphthous ulcer = 1 Pyoderma gangrenosum = 1 Anal Fissure = 1 New Fistula = 1 Abscess = 1 Total Harvey Bradshaw Index score: [sum of all above items]	2. Abdominal Pain Descriptors Abdominal pain may include cramping and discomfort. It does not have to be just "pain" as we know it. Below are some descriptors to help you rank your category of abdominal pain. Mild: You're aware that the abdominal pain is there but it does not interfere with your life and you continue with activities such as work and pleasure. You feel and hear rumbles, gurgles and cramps. Moderate: You're aware of your abdominal pain and must alter your activities to manage the pain (ie. lie down to rest, postpone shopping trips until later, and take Tylenol). The pain interferes with your life and daily activities. You may have to miss work or pleasure activities on occasion. Severe: Your abdominal pain causes you to stop all activity. You are frequently in bed because of the pain, you call in sick to work and cancel all activities.
Remission = <5	Ni .


	atient Name:	
Activity	ate of Birth:	
Patient, please enter number of daily bowel motions you w when in remission or before your diagnosis or symptoms of ulcerative colitis began. This number will be Your Normal:	2000A-11-000VR	
Patients, please complete Questions number 1 and 2.		
Stool Frequency (based on the past 3 days)		
Normal number of stools	= 0	
1-2 stools more than normal	= 1	
3-4 stools more than normal	= 2	
5 or more stools more than normal	= 3	
2. Rectal Bleeding (based on the past 3 days)		
No blood seen	= 0	
Streaks of blood with stool less than half the time	= 1	
Obvious blood with stool most of the time	= 2	
Blood alone passed	= 3	
Physician, please complete Questions number 3.		
3. Physician's Global Assessment (to be completed by	Obuglalan VERSITY	
Normal (sub scores are mostly 0)	= 0	
Mild disease (sub scores are mostly 1)	= 1	
Moderate disease (sub scores are mostly 1 to 2) = 2		
Severe disease (sub scores are mostly 2 to 3)	= 3	
The physician's Global Assessment acknowledges the S and functional assessment and other observations such status		
Total Partial Mayo Index Score [sum of all above item:	1	

ΑΠΟΤΕΛΕΣΜΑΤΑ


Μελέτη ασθενών της κλινικής μας

- 71 ασθενείς (44 άνδρες, 27 γυναίκες)
- Διάμεση ηλικία 39 έτη (εύρος 17-77)
- 48 NC και 23 EK
- Μέση διάρκεια νόσου 11,4 έτη


Εξωεντερικές εκδηλώσεις (ΕΕΕ) (N=71)



Επιπολασμός εξωεντερικών εκδηλώσεων σε ασθενείς με ΙΦΝΕ (%)




Χρόνιος σπονδυλικός πόνος (ΧΣΠ) σε ασθενείς με ΙΦΝΕ (N=71)






Βαθμός ακτινογραφικής ιερολαγονίτιδας (ανά πλευρά) σε ασθενείς με ΙΦΝΕ

- Ακτινογραφία ιερολαγονίων έγινε σε 31 ασθενείς
- Ιερολαγονίτιδα βαθμού 2 αμφοτερόπλευρα ή ≥3 ετερόπλευρα είχαν 12 (38,7%)
 ασθενείς




Βιολογικοί παράγοντες στην αξονική προσβολή



ΒΠ, Βιολογικός Παράγοντας ΧΣΠ, Χρόνιος Σπονδυλικός Πόνος Inf, Infliximab Ada, Adalimumab

Επίδραση βιολογικών παραγόντων στην αξονική προσβολή του σκελετού σε ασθενείς με ΙΦΝΕ



Συμπεράσματα

• Περισσότεροι από τους μισούς ασθενείς με ΙΦΝΕ αναφέρουν μυοσκελετικές εκδηλώσεις

• Αναγκαία η συστηματική αναζήτηση και αντιμετώπισή τους

 Η αγωγή με anti-TNF μονοκλωνικά αντισώματα φαίνεται αποτελεσματικότερη στην αντιμετώπιση τόσο των εντερικών όσο και των σπονδυλικών συμπτωμάτων

